{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:35:29Z","timestamp":1793828129889,"version":"4.6.1"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    Diabetic retinopathy (DR) is the major ocular complication of diabetes mellitus, and is a problem with significant global health impact. Major advances in diagnostics, technology and treatment have already revolutionized how we manage DR in the early part of the 21\n                    <jats:sup>st<\/jats:sup>\n                    century. For example, the accessibility of imaging with optical coherence tomography, and the development of anti-vascular endothelial growth factor (VEGF) treatment are just some of the landmark developments that have shaped the DR landscape over the last few decades. Yet, there are still more exciting advances being made. Looking forward to 2030, many of these ongoing developments are likely to further transform the field. First, epidemiologic projections show that the global burden of DR is not only increasing, but also shifting from high-income countries towards middle- and low-income areas. Second, better understanding of disease pathophysiology is placing greater emphasis on retinal neural dysfunction and non-vascular aspects of diabetic retinal disease. Third, a wealth of information is becoming available from newer imaging modalities such as widefield imaging systems and optical coherence tomography angiography. Fourth, artificial intelligence for screening, diagnosis and prognostication of DR will become increasingly accessible and important. Fifth, new pharmacologic agents targeting other non-VEGF-driven pathways, and novel therapeutic strategies such as gene therapy are being developed for DR. Finally, the classification system for diabetic retinal disease will need to be continually updated to keep pace with new developments. In this article, we discuss these major trends in DR that we expect to see in 2030 and beyond.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2022.1077669","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T05:28:03Z","timestamp":1673242083000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":482,"title":["Diabetic retinopathy: Looking forward to 2030"],"prefix":"10.3389","volume":"13","author":[{"given":"Tien-En","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12119","article-title":"Prevalence of diabetic retinopathy in type 2 diabetes in developing and developed countries","volume":"30","author":"Ruta","year":"2013","journal-title":"Diabetes Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.12696","article-title":"Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: A review","volume":"44","author":"Ting","year":"2016","journal-title":"Clin Exp Ophthalmol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0615","article-title":"Rates of progression in diabetic retinopathy during different time periods: A systematic review and meta-analysis","volume":"32","author":"Wong","year":"2009","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/09286586.2016.1193618","article-title":"Ten emerging trends in the epidemiology of diabetic retinopathy","volume":"23","author":"Sabanayagam","year":"2016","journal-title":"Ophthalmic Epidemiol"},{"key":"B6","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(03)00475-5","article-title":"Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales","volume":"110","author":"Wilkinson","year":"2003","journal-title":"Ophthalmology"},{"key":"B8","article-title":"Early photocoagulation for diabetic retinopathy. ETDRS report number 9","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000048","article-title":"Pan retinal photocoagulation for proliferative diabetic retinopathy: pattern scan laser versus argon laser","volume":"25","author":"Alasil","year":"2014","journal-title":"Curr Opin Ophthalmol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181c70127","article-title":"Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser","volume":"30","author":"Nagpal","year":"2010","journal-title":"Retina"},{"key":"B11","doi-asserted-by":"publisher","first-page":"OCT1","DOI":"10.1167\/iovs.16-19963","article-title":"The development, commercialization, and impact of optical coherence tomography","volume":"57","author":"Fujimoto","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11892-016-0787-6","article-title":"Surgery for diabetic eye complications","volume":"16","author":"Berrocal","year":"2016","journal-title":"Curr Diabetes Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.321","article-title":"Visual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: the DRIVE UK study","volume":"26","author":"Gupta","year":"2012","journal-title":"Eye (Lond)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ajo.2013.02.008","article-title":"Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials","volume":"156","author":"Zhang","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: Systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.12.1754","article-title":"The economic burden of major adult visual disorders in the united states","volume":"124","author":"Rein","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12886-016-0318-x","article-title":"Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up","volume":"16","author":"Romero-Aroca","year":"2016","journal-title":"BMC Ophthalmol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.482503","article-title":"Burden of illness of diabetic macular edema: Literature review","volume":"26","author":"Chen","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.08.021","article-title":"Cost-effectiveness of a national telemedicine diabetic retinopathy screening program in Singapore","volume":"123","author":"Nguyen","year":"2016","journal-title":"Ophthalmology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-1_part_2-199601011-00017","article-title":"Cost-effectiveness of detecting and treating diabetic retinopathy","volume":"124","author":"Javitt","year":"1996","journal-title":"Ann Intern Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(89)32923-x","article-title":"Cost effectiveness of current approaches to the control of retinopathy in type I diabetics","volume":"96","author":"Javitt","year":"1989","journal-title":"Ophthalmology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30411-5","article-title":"Screening for diabetic retinopathy: New perspectives and challenges","volume":"8","author":"Vujosevic","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.2536","article-title":"Diabetic retinal neurodegeneration-should we redefine retinopathy from diabetes","volume":"137","author":"Sohn","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1522014113","article-title":"Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus","volume":"113","author":"Sohn","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.visres.2017.03.003","article-title":"Diabetic retinopathy is a neurodegenerative disorder","volume":"139","author":"Lynch","year":"2017","journal-title":"Vision Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-21873","article-title":"Approach for a clinically useful comprehensive classification of vascular and neural aspects of diabetic retinal disease","volume":"59","author":"Abramoff","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0125919","DOI":"10.1371\/journal.pone.0125919","article-title":"Peripapillary retinal nerve fiber layer changes in preclinical diabetic retinopathy: A meta-analysis","volume":"10","author":"Chen","year":"2015","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.2537","article-title":"Longitudinal changes in the peripapillary retinal nerve fiber layer thickness of patients with type 2 diabetes","volume":"137","author":"Lim","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317322","article-title":"Longitudinal analysis of microvascular perfusion and neurodegenerative changes in early type 2 diabetic retinal disease","volume":"106","author":"Aschauer","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-21168","article-title":"Loss of melanopsin-expressing retinal ganglion cells in patients with diabetic retinopathy","volume":"58","author":"Obara","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1985.01050010055018","article-title":"Contrast sensitivity in diabetics with and without background retinopathy","volume":"103","author":"Sokol","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.12.1809","article-title":"Multifocal electroretinogram and short-wavelength automated perimetry measures in diabetic eyes with little or no retinopathy","volume":"122","author":"Han","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF00155037","article-title":"Steady-state pattern electroretinogram in insulin-dependent diabetics with no or minimal retinopathy","volume":"73","author":"Falsini","year":"1989","journal-title":"Doc Ophthalmol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-10927","article-title":"Early visual deficits in streptozotocin-induced diabetic long evans rats","volume":"54","author":"Aung","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02226.x","article-title":"The post-illumination pupil response of melanopsin-expressing intrinsically photosensitive retinal ganglion cells in diabetes","volume":"90","author":"Feigl","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14116","article-title":"Retinal neural dysfunction in diabetes revealed with handheld chromatic pupillometry","volume":"50","author":"Tan","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003070","article-title":"Need for a new classification of diabetic retinopathy","volume":"41","author":"Jampol","year":"2021","journal-title":"Retina"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.10.008","article-title":"Updating the staging system for diabetic retinal disease","volume":"128","author":"Sun","year":"2021","journal-title":"Ophthalmology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.05.007","article-title":"Classification and guidelines for widefield imaging: Recommendations from the international widefield imaging study group","volume":"3","author":"Choudhry","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14118","article-title":"Optos wide-field imaging versus conventional camera imaging in Danish patients with type 2 diabetes","volume":"97","author":"Byberg","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.05.004","article-title":"Peripheral lesions identified by mydriatic ultrawide field imaging: distribution and potential impact on diabetic retinopathy severity","volume":"120","author":"Silva","year":"2013","journal-title":"Ophthalmology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamaophthalmol.2018.4982","article-title":"Comparison of early treatment diabetic retinopathy study standard 7-field imaging with ultrawide-field imaging for determining severity of diabetic retinopathy","volume":"137","author":"Aiello","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S79448","article-title":"Optomap ultrawide field imaging identifies additional retinal abnormalities in patients with diabetic retinopathy","volume":"9","author":"Price","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.02.012","article-title":"Hemorrhage and\/or microaneurysm severity and count in ultrawide field images and early treatment diabetic retinopathy study photography","volume":"124","author":"Silva","year":"2017","journal-title":"Ophthalmology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.01.008","article-title":"Peripheral lesions identified on ultrawide field imaging predict increased risk of diabetic retinopathy progression over 4 years","volume":"122","author":"Silva","year":"2015","journal-title":"Ophthalmology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.05.021","article-title":"Quantitative assessment of the severity of diabetic retinopathy","volume":"218","author":"Sadda","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.3131","article-title":"Association of predominantly peripheral lesions on ultra-widefield imaging and the risk of diabetic retinopathy worsening over time","volume":"140","author":"Marcus","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.3130","article-title":"Association of ultra-widefield fluorescein angiography\u2013identified retinal nonperfusion and the risk of diabetic retinopathy worsening over time","volume":"140","author":"Silva","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3390\/jcm9061723","article-title":"Optical coherence tomography angiography in diabetes and diabetic retinopathy","volume":"9","author":"Chua","year":"2020","journal-title":"J Clin Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"11751","DOI":"10.1038\/s41598-019-47770-9","article-title":"Global assessment of retinal arteriolar, venular and capillary microcirculations using fundus photographs and optical coherence tomography angiography in diabetic retinopathy","volume":"9","author":"Tan","year":"2019","journal-title":"Sci Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01233-y","article-title":"Optical coherence tomography angiography in diabetic retinopathy: An updated review","volume":"35","author":"Sun","year":"2021","journal-title":"Eye (Lond)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.5877","article-title":"Optical coherence tomographic angiography in type 2 diabetes and diabetic retinopathy","volume":"135","author":"Ting","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-21787","article-title":"Quantifying microvascular abnormalities with increasing severity of diabetic retinopathy using optical coherence tomography angiography","volume":"58","author":"Nesper","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.1.9","article-title":"Diabetic macular ischemia: Influence of optical coherence tomography angiography parameters on changes in functional outcomes over one year","volume":"62","author":"Tsai","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.04.024","article-title":"Optical coherence tomography angiography avascular area association with 1-year treatment requirement and disease progression in diabetic retinopathy","volume":"217","author":"You","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ajo.2020.06.009","article-title":"Macular and peripapillary optical coherence tomography angiography metrics predict progression in diabetic retinopathy: A Sub-analysis of TIME-2b study data","volume":"219","author":"Custo Greig","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.06.016","article-title":"OCT angiography metrics predict progression of diabetic retinopathy and development of diabetic macular edema: A prospective study","volume":"126","author":"Sun","year":"2019","journal-title":"Ophthalmology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-313173","article-title":"Artificial intelligence and deep learning in ophthalmology","volume":"103","author":"Ting","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.17216","article-title":"Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs","volume":"316","author":"Gulshan","year":"2016","journal-title":"JAMA"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.18152","article-title":"Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes","volume":"318","author":"Ting","year":"2017","journal-title":"JAMA"},{"key":"B63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41746-018-0040-6","article-title":"Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices","volume":"1","author":"Abr\u00e0moff","year":"2018","journal-title":"NPJ Digit Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0164","article-title":"The value of automated diabetic retinopathy screening with the EyeArt system: A study of more than 100,000 consecutive encounters from people with diabetes","volume":"21","author":"Bhaskaranand","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(20)30060-1","article-title":"Artificial intelligence for teleophthalmology-based diabetic retinopathy screening in a national programme: an economic analysis modelling study","volume":"2","author":"Xie","year":"2020","journal-title":"Lancet Digit Health"},{"key":"B66","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41467-019-13922-8","article-title":"Predicting optical coherence tomography-derived diabetic macular edema grades from fundus photographs using deep learning","volume":"11","author":"Varadarajan","year":"2020","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0107-6","article-title":"Clinically applicable deep learning for diagnosis and referral in retinal disease","volume":"24","author":"De Fauw","year":"2018","journal-title":"Nat Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061269","article-title":"Automatic segmentation of retinal fluid and photoreceptor layer from optical coherence tomography images of diabetic macular edema patients using deep learning and associations with visual acuity","volume":"10","author":"Hsu","year":"2022","journal-title":"Biomedicines"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.2457","article-title":"Quantification of fluid resolution and visual acuity gain in patients with diabetic macular edema using deep learning: A Post hoc analysis of a randomized clinical trial","volume":"138","author":"Roberts","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100972","article-title":"AI-Based monitoring of retinal fluid in disease activity and under therapy","volume":"86","author":"Schmidt-Erfurth","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.10.031","article-title":"Fully automated detection and quantification of macular fluid in OCT using deep learning","volume":"125","author":"Schlegl","year":"2018","journal-title":"Ophthalmology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.0070","article-title":"Comparison of subjective assessment and precise quantitative assessment of lesion distribution in diabetic retinopathy","volume":"136","author":"Sears","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.0440","article-title":"Retinal nonperfusion characteristics on ultra-widefield angiography in eyes with severe nonproliferative diabetic retinopathy and proliferative diabetic retinopathy","volume":"137","author":"Nicholson","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.05.034","article-title":"Quantitative ultra-widefield angiography and diabetic retinopathy severity: An assessment of panretinal leakage index, ischemic index and microaneurysm count","volume":"126","author":"Ehlers","year":"2019","journal-title":"Ophthalmology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2021.05.001","article-title":"Artificial intelligence for prediction of anti-VEGF treatment burden in retinal diseases: Towards precision medicine","volume":"5","author":"Tan","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.04.007","article-title":"Guidelines on diabetic eye care: The international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings","volume":"125","author":"Wong","year":"2018","journal-title":"Ophthalmology"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"key":"B78","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.oret.2018.06.005","article-title":"Ranibizumab induces regression of diabetic retinopathy in most patients at high risk of progression to proliferative diabetic retinopathy","volume":"2","author":"Wykoff","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2018.02.011","article-title":"Evaluating the impact of intravitreal aflibercept on diabetic retinopathy progression in the VIVID-DME and VISTA-DME studies","volume":"2","author":"Mitchell","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.2809","article-title":"Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: Results from the PANORAMA randomized clinical trial","volume":"139","author":"Brown","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.0606","article-title":"Effect of intravitreous anti-vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: The protocol W randomized clinical trial","volume":"139","author":"Maturi","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.06.022","article-title":"Widefield OCT-angiography and fluorescein angiography assessments of nonperfusion in diabetic retinopathy and edema treated with anti-vascular endothelial growth factor","volume":"126","author":"Couturier","year":"2019","journal-title":"Ophthalmology"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.02.003","article-title":"Aflibercept reduces retinal hemorrhages and intravitreal microvascular abnormalities but not venous beading: Secondary analysis of the CLARITY study","volume":"4","author":"Pearce","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"B86","first-page":"1345","article-title":"Evaluation of 8 mg intravitreal aflibercept injection for neovascular age-related macular degeneration: Results from the phase 2 CANDELA study","volume":"63","author":"Brown","year":"2022","journal-title":". Investigative Ophthalmology Visual Sci"},{"key":"B87","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.795010","article-title":"Gene-based therapeutics for acquired retinal disease: Opportunities and progress","volume":"12","author":"Tan","year":"2021","journal-title":"Front Genet"},{"key":"B89","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/APO.0000000000000362","article-title":"Creating an ocular biofactory: Surgical approaches in gene therapy for acquired retinal diseases","volume":"10","author":"Xu","year":"2021","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"B90","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/OPTH.S128509","article-title":"Anti-VEGF treatment of diabetic macular edema in clinical practice: Effectiveness and patterns of use (ECHO study report 1)","volume":"11","author":"Blinder","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233595","article-title":"Effectiveness and safety of ranibizumab 0.5 mg in treatment-na\u00efve patients with diabetic macular edema: Results from the real-world global LUMINOUS study","volume":"15","author":"Mitchell","year":"2020","journal-title":"PloS One"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S281501","article-title":"Real-world outcomes in patients with diabetic macular edema treated long term with ranibizumab (VISION study)","volume":"14","author":"Van Aken","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-315933","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: A real-world analysis of 28 658 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"B94","first-page":"2207","article-title":"Updating the diabetic retinal disease staging system through the restoring vision moonshot\u2122","volume":"63","author":"Sun","year":"2022","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"B95","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0161-6420(13)38012-9","article-title":"Grading diabetic retinopathy from stereoscopic color fundus photographs\u2013an extension of the modified airlie house classification. ETDRS report number 10","volume":"98","year":"1991","journal-title":"Ophthalmology"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1077669\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T05:28:10Z","timestamp":1673242090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1077669\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":95,"alternative-id":["10.3389\/fendo.2022.1077669"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1077669","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"article-number":"1077669"}}